CA2157577A1 - Growth differentiation factor-8 - Google Patents
Growth differentiation factor-8Info
- Publication number
- CA2157577A1 CA2157577A1 CA002157577A CA2157577A CA2157577A1 CA 2157577 A1 CA2157577 A1 CA 2157577A1 CA 002157577 A CA002157577 A CA 002157577A CA 2157577 A CA2157577 A CA 2157577A CA 2157577 A1 CA2157577 A1 CA 2157577A1
- Authority
- CA
- Canada
- Prior art keywords
- gdf
- cell
- vector
- antibody
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004472 Myostatin Human genes 0.000 title claims abstract 15
- 108010056852 Myostatin Proteins 0.000 title claims abstract 15
- 108091033319 polynucleotide Proteins 0.000 claims abstract 9
- 102000040430 polynucleotide Human genes 0.000 claims abstract 9
- 239000002157 polynucleotide Substances 0.000 claims abstract 9
- 238000000034 method Methods 0.000 claims 29
- 210000004027 cell Anatomy 0.000 claims 11
- 239000013598 vector Substances 0.000 claims 8
- 239000002502 liposome Substances 0.000 claims 5
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 229930186217 Glycolipid Natural products 0.000 claims 2
- 238000001246 colloidal dispersion Methods 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 241001493065 dsRNA viruses Species 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000007850 fluorescent dye Substances 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 210000000663 muscle cell Anatomy 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
Abstract
Growth differentiation factor-8 (GDF-8) is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of using the GDF-8 polypeptide and polynucleotide sequences.
Claims (43)
1. Substantially pure growth differentiation factor-8 (GDF-8) and functional fragments thereof.
2. An isolated polynucleotide sequence encoding the GDF-8 polypeptide of claim 1.
3. The polynucleotide of claim 2, wherein the GDF-8 nucleotide sequence is selected from the group consisting of the nucleic acid sequence of a. FIGURE 5a, wherein T can also be U;
b. FIGURE 5b, wherein T can also be U;
c. nucleic acid sequences complementary to FIGURE 5a;
d. nucleic acid sequences complementary to FIGURE 5b;
e. fragments of a. or c. that are at least 15 bases in length and that will selectively hybridize to genomic DNA which encodes the GDF-8 protein of FIGURE 5a; and f. fragments of b. or d. that are at least 15 bases in length and that will selectively hybridize to genomic DNA which encodes the GDF-8 protein of FIGURE 5b.
b. FIGURE 5b, wherein T can also be U;
c. nucleic acid sequences complementary to FIGURE 5a;
d. nucleic acid sequences complementary to FIGURE 5b;
e. fragments of a. or c. that are at least 15 bases in length and that will selectively hybridize to genomic DNA which encodes the GDF-8 protein of FIGURE 5a; and f. fragments of b. or d. that are at least 15 bases in length and that will selectively hybridize to genomic DNA which encodes the GDF-8 protein of FIGURE 5b.
4. The polynucleotide sequence of claim 2, wherein the polynucleotide is isolated from a mammalian cell.
5. The polynucleotide of claim 4, wherein the mammalian cell is selected from the group consisting of mouse, rat, and human cell.
6. An expression vector including the polynucleotide of claim 2
7. The vector of claim 6, wherein the vector is a plasmid.
8. The vector of claim 6, wherein the vector is a virus.
9. A host cell stably transformed with the vector of claim 6.
10. The host cell of claim 9, wherein the cell is prokaryotic.
11. The host cell of claim 9, wherein the cell is eukaryotic.
12. Antibodies reactive with the polypeptide of claim 1 or fragments thereof.
13. The antibodies of claim 12, wherein the antibodies are polyclonal.
14. The antibodies of claim 12, wherein the antibodies are monoclonal.
15. A method of detecting a cell proliferative disorder comprising contacting the antibody of claim 12 with a specimen of a subject suspected of having a GDF-8 associated disorder and detecting binding of the antibody.
16. The method of claim 15, wherein the cell is a muscle cell.
17. The method of claim 15, wherein the detecting is in vivo.
18. The method of claim 17, wherein the antibody is detectably labeled.
19. The method of claim 18, wherein the detectable label is selected from the group consisting of a radioisotope, a fluorescent compound, a bioluminescent compound and a chemiluminescent compound.
20. The method of claim 15, wherein the detection is in vitro.
21. The method of claim 20, wherein the antibody is detectably labeled.
22. The method of claim 21, wherein the label is selected from the group consisting of a radioisotope, a fluorescent compound, a bioluminescent compound, a chemoluminescent compound and an enzyme.
23. A method of treating a cell proliferative disorder associated with expression of GDF-8, comprising contacting the cells with a reagent which suppresses the GDF-8 activity.
24. The method of claim 23, wherein the reagent is an anti-GDF-8 antibody.
25. The method of claim 23, wherein the reagent is a GDF-8 antisense sequence.
26. The method of claim 23, wherein the cell is a muscle cell.
27. The method of claim 23, wherein the reagent which suppresses GDF-8 activity is introduced to a cell using a vector.
28. The method of claim 27, wherein the vector is a colloidal dispersion system.
29. The method of claim 28, wherein the colloidal dispersion system is a liposome.
30. The method of claim 29, wherein the liposome is essentially target specific.
31. The method of claim 30, wherein the liposome is anatomically targeted.
32. The method of claim 31, wherein the liposome is mechanistically targeted.
33. The method of claim 32, wherein the mechanistic targeting is passive.
34. The method of claim 32, wherein the mechanistic targeting is active.
35. The method of claim 34, wherein the liposome is actively targeted by coupling with a moiety selected from the group consisting of a sugar, a glycolipid, and a protein.
36. The method of claim 35, wherein the protein moiety is an antibody.
37. The method of claim 36, wherein the vector is a virus.
38. The method of claim 37, wherein the virus is an RNA virus.
39. The method of claim 38, wherein the RNA virus is a retrovirus.
40. The method of claim 39, wherein the retrovirus is essentially target specific.
41. The method of claim 40, wherein a moiety for target specificity is encoded by a polynucleotide inserted into the retroviral genome.
42. The method of claim 40, wherein a moiety for target specificity is selected from the group consisting of a sugar, a glycolipid, and a protein.
43. The method of claim 42, wherein the protein is an antibody.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3392393A | 1993-03-19 | 1993-03-19 | |
US08/033,923 | 1993-03-19 | ||
PCT/US1994/003019 WO1994021681A1 (en) | 1993-03-19 | 1994-03-18 | Growth differentiation factor-8 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2157577A1 true CA2157577A1 (en) | 1994-09-29 |
CA2157577C CA2157577C (en) | 2009-11-17 |
Family
ID=21873232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002157577A Expired - Lifetime CA2157577C (en) | 1993-03-19 | 1994-03-18 | Growth differentiation factor-8 |
Country Status (8)
Country | Link |
---|---|
US (5) | US5827733A (en) |
EP (2) | EP1333035A3 (en) |
JP (4) | JPH09507829A (en) |
CA (1) | CA2157577C (en) |
DE (1) | DE69432815T2 (en) |
DK (1) | DK0690873T3 (en) |
ES (1) | ES2201076T3 (en) |
WO (1) | WO1994021681A1 (en) |
Families Citing this family (149)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3504263B2 (en) | 1991-11-04 | 2004-03-08 | ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー | Recombinant bone morphogenetic protein heterodimers, compositions and uses |
US7393682B1 (en) * | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
DE69432815T2 (en) * | 1993-03-19 | 2003-12-11 | Univ Johns Hopkins Med | GROWTH FACTOR-8 |
US6465239B1 (en) | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
US5994618A (en) * | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
US20030074680A1 (en) * | 1993-03-19 | 2003-04-17 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
DE69433530T2 (en) | 1993-05-12 | 2005-01-05 | Genetics Institute, LLC, Cambridge | BMP-11 COMPOSITIONS |
US6713302B1 (en) * | 1993-07-09 | 2004-03-30 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-6 |
US7332575B2 (en) | 1994-03-18 | 2008-02-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species |
DK0776337T3 (en) * | 1994-07-08 | 2005-12-12 | Univ Johns Hopkins Med | Growth differentiation factor-11 |
US6008434A (en) | 1994-07-08 | 1999-12-28 | Johns Hopkins University School Of Medicine | Growth differentiation factor-11 transgenic mice |
US20030167492A1 (en) | 1994-07-08 | 2003-09-04 | Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same |
US5846770A (en) * | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
US5635372A (en) * | 1995-05-18 | 1997-06-03 | Genetics Institute, Inc. | BMP-15 compositions |
AU699918B2 (en) | 1995-06-05 | 1998-12-17 | Genetics Institute, Llc | Methods and compositions for healing and repair of connective tissue attachment |
US5700774A (en) * | 1996-03-26 | 1997-12-23 | Genetics Institute, Inc. | Compositions comprising bone morphogenic proteins and truncated parathyroid hormone related peptide, and methods of inducing cartilage by administration of same |
US5965403A (en) | 1996-09-18 | 1999-10-12 | Genetics Institute, Inc. | Nucleic acids encoding bone morphogenic protein-16 (BMP-16) |
US20010016646A1 (en) | 1998-03-20 | 2001-08-23 | David C. Rueger | Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects |
US7041641B2 (en) | 1997-03-20 | 2006-05-09 | Stryker Corporation | Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
CA2291514C (en) | 1997-05-30 | 2011-07-12 | Creative Biomolecules, Inc. | Methods for evaluating tissue morphogenesis and activity |
US20070067859A1 (en) * | 1997-07-14 | 2007-03-22 | Michel Georges | Double-muscling in mammals |
US6103466A (en) * | 1997-07-14 | 2000-08-15 | University Of Liege | Double-muscling in mammals |
DE69841139D1 (en) * | 1997-07-14 | 2009-10-22 | Univ Liege | MUTATIONS IN MYOSTATINGEN INCREASE MUSCLE MASS IN MAMMALS |
US6696260B1 (en) * | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
US6656475B1 (en) * | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
US20020052026A1 (en) | 1997-10-08 | 2002-05-02 | Steven M. Vicik | Methods of refolding proteins |
US6027917A (en) | 1997-12-10 | 2000-02-22 | Genetics Institute, Inc. | Bone morphogenetic protein (BMP)-17 and BMP-18 compositions |
CA2319703C (en) * | 1998-02-05 | 2005-09-20 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
US6369201B1 (en) * | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
US6004937A (en) * | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
JP4544742B2 (en) | 1998-05-06 | 2010-09-15 | メタモーフイクス・インコーポレーテツド | Treatment of diabetes by inhibition of GDF-8 |
US7147839B2 (en) | 1998-05-29 | 2006-12-12 | Curis, Inc. | Methods for evaluating tissue morphogenesis and activity |
JP2002520043A (en) * | 1998-07-15 | 2002-07-09 | メタモーフイクス・インコーポレーテツド | Growth differentiation factor promoter and uses thereof |
NZ513642A (en) * | 1999-01-21 | 2004-02-27 | Metamorphix Inc | Growth differentiation factor inhibitors and uses therefor |
US6727224B1 (en) | 1999-02-01 | 2004-04-27 | Genetics Institute, Llc. | Methods and compositions for healing and repair of articular cartilage |
DE19906096A1 (en) | 1999-02-13 | 2000-08-17 | Walter Sebald | Protein with a heparin-binding epitope |
US6284882B1 (en) * | 1999-06-10 | 2001-09-04 | Abbott Laboratories | Myostatin gene promoter and inhibition of activation thereof |
AU4889100A (en) | 1999-07-30 | 2001-02-01 | Pfizer Products Inc. | Myostatin regulatory region, nucleotide sequence determination and methods for its use |
US6756215B1 (en) * | 2000-10-20 | 2004-06-29 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Functionalized TGF-β fusion proteins |
US7037501B2 (en) * | 2001-01-04 | 2006-05-02 | Regents Of The University Of Minnesota | Myostatin immnoconjugate |
TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
KR100420798B1 (en) * | 2001-02-10 | 2004-03-02 | (주)알에이싸이언스 | Peptide vector |
TWI267378B (en) | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
US6798160B2 (en) * | 2001-11-02 | 2004-09-28 | Honda Giken Kogyo Kabushiki Kaisha | Electric working machine |
WO2003072714A2 (en) | 2002-02-21 | 2003-09-04 | Wyeth | Follistatin domain containing proteins |
IL163525A0 (en) * | 2002-02-21 | 2005-12-18 | Wyeth Corp | A follistatin domain containing protein |
WO2004024092A2 (en) * | 2002-09-16 | 2004-03-25 | Wyeth | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
AR047392A1 (en) * | 2002-10-22 | 2006-01-18 | Wyeth Corp | NEUTRALIZATION OF ANTIBODIES AGAINST GDF 8 AND ITS USE FOR SUCH PURPOSES |
US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
KR20130036378A (en) | 2002-12-20 | 2013-04-11 | 암겐 인코포레이티드 | Binding agents which inhibit myostatin |
WO2004108157A2 (en) | 2003-06-02 | 2004-12-16 | Wyeth | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
CN1878565B (en) | 2003-09-12 | 2011-01-12 | 惠氏公司 | Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins |
BRPI0418317A (en) * | 2003-12-31 | 2007-05-02 | Schering Plough Ltd | neutralization epitope-based growth enhancement vaccine |
PT1737734E (en) | 2004-03-10 | 2010-11-11 | Scil Technology Gmbh | Coated implants, their manufacturing and use thereof |
ES2384176T3 (en) * | 2004-03-23 | 2012-07-02 | Eli Lilly & Company | Anti-myostatin antibodies |
JP4688483B2 (en) * | 2004-04-15 | 2011-05-25 | 株式会社テクノネットワーク四国 | Follistatin variant polypeptide |
AU2005247871A1 (en) | 2004-04-27 | 2005-12-08 | Research Development Foundation | Antagonism of TGF-beta superfamily receptor signaling |
CA2567405A1 (en) | 2004-05-25 | 2005-12-08 | Stryker Corporation | Use of morphogenic proteins for treating cartilage defects |
BRPI0514253A (en) * | 2004-08-12 | 2008-06-03 | Wyeth Corp | combination therapy for diabetes, obesity and cardiovascular disease using compositions containing gdf-8 inhibitors |
US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
EP1831372A2 (en) * | 2004-12-30 | 2007-09-12 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
WO2006081379A1 (en) * | 2005-01-26 | 2006-08-03 | Wyeth | Use of sfrps as markers of bmp activity |
CA2596506C (en) | 2005-02-09 | 2021-04-06 | Avi Biopharma, Inc. | Antisense composition and method for treating muscle atrophy |
CA2601086A1 (en) * | 2005-03-23 | 2006-10-12 | Wyeth | Detection of an immune response to gdf-8 modulating agents |
EP1863518A2 (en) * | 2005-03-30 | 2007-12-12 | Wyeth | Methods for stimulating hair growth by administering bmps |
ES2534760T3 (en) | 2005-08-19 | 2015-04-28 | Wyeth Llc | Antagonist antibodies against GDF-8 and their uses in the treatment of ALS and other disorders associated with GDF-8 |
KR101135220B1 (en) * | 2005-10-06 | 2012-04-24 | 일라이 릴리 앤드 캄파니 | Anti-myostatin antibodies |
UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
EP1968621A2 (en) * | 2005-12-06 | 2008-09-17 | Amgen Inc. | Uses of myostatin antagonists |
US8147860B2 (en) | 2005-12-06 | 2012-04-03 | Etex Corporation | Porous calcium phosphate bone material |
CA2641860C (en) | 2006-02-09 | 2015-07-14 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating bone |
DK3056568T3 (en) | 2006-03-31 | 2021-11-01 | Chugai Pharmaceutical Co Ltd | PROCEDURES FOR CONTROL OF THE BLOOD PHARMACOKINETICS OF ANTIBODIES |
EP2035030A2 (en) | 2006-05-17 | 2009-03-18 | Stryker Corporation | Use of a soluble morphogenic protein complex for treating cartilage defects |
JP5484047B2 (en) | 2006-06-30 | 2014-05-07 | バイオミメティック セラピューティクス, エルエルシー | PDGF-biomatrix composition and method for treating rotator cuff injury |
US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
US8524265B2 (en) | 2006-08-17 | 2013-09-03 | Warsaw Orthopedic, Inc. | Medical implant sheets useful for tissue regeneration |
PL2066695T3 (en) | 2006-09-05 | 2013-08-30 | Lilly Co Eli | Anti-myostatin antibodies |
AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
ES2447516T3 (en) | 2006-12-21 | 2014-03-12 | Stryker Corporation | Sustained release formulations comprising BMP-7 crystals |
US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
US7947646B2 (en) | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
US8236751B2 (en) * | 2007-03-07 | 2012-08-07 | The Johns Hopkins University | Methods of increasing muscle mass using follistatin-like related gene (FLRG) |
US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
RS55735B1 (en) | 2007-08-03 | 2017-07-31 | Summit (Oxford) Ltd | Drug combinations for the treatment of duchenne muscular dystrophy |
JP5323832B2 (en) | 2007-08-07 | 2013-10-23 | アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー | Protein preparation containing GDF-5 in acidic aqueous solution |
CN106519025B (en) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | Method for changing isoelectric point of antibody by using amino acid substitution of CDR |
JP2011514331A (en) | 2008-02-13 | 2011-05-06 | キース フルスカ, | BMP-7 for use in the treatment of angiosclerosis |
US8461108B2 (en) | 2008-03-07 | 2013-06-11 | Myoscience, Inc. | Subdermal tissue remodeling using myostatin, methods and related systems |
KR102469853B1 (en) | 2008-04-11 | 2022-11-22 | 추가이 세이야쿠 가부시키가이샤 | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
CA2720845A1 (en) | 2008-04-14 | 2009-10-22 | Advanced Technologies And Regenerative Medicine, Llc | Liquid buffered gdf-5 formulations |
AU2009291828C1 (en) | 2008-09-09 | 2016-03-17 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries |
PE20120206A1 (en) | 2008-11-26 | 2012-03-09 | Amgen Inc | ACTIVIN IIB RECEPTOR POLYPEPTIDE VARIANTS |
UY32341A (en) | 2008-12-19 | 2010-07-30 | Glaxo Group Ltd | NEW ANTIGEN UNION PROTEINS |
JP5819734B2 (en) | 2009-02-12 | 2015-11-24 | ストライカー コーポレイションStryker Corporation | Compositions and methods for minimally invasive systemic delivery of TGF-β superfamily member-containing proteins |
CA2752157A1 (en) | 2009-02-12 | 2010-08-19 | Stryker Corporation | Peripheral administration of proteins including tgf-.beta. superfamily members for systemic treatment of disorders and disease |
WO2010110974A1 (en) | 2009-03-24 | 2010-09-30 | Stryker Corporation | Methods and compositions for tissue engineering |
US8609127B2 (en) | 2009-04-03 | 2013-12-17 | Warsaw Orthopedic, Inc. | Medical implant with bioactive material and method of making the medical implant |
WO2010144696A1 (en) | 2009-06-11 | 2010-12-16 | Burnham Institute For Medical Research | Directed differentiation of stem cells |
WO2011031856A1 (en) | 2009-09-09 | 2011-03-17 | Stryker Corporation | Bmp -7 for use in treating pain induced by injuries and diseases of an articular joint |
ES2387379T3 (en) | 2009-09-17 | 2012-09-21 | Stryker Corporation | Buffers to control the pH of bone morphogenetic proteins |
EP2516456A1 (en) | 2009-12-22 | 2012-10-31 | Stryker Corporation | Bmp-7 variants with reduced immunogenicity |
JP6144049B2 (en) | 2010-02-22 | 2017-06-07 | バイオミメティック セラピューティクス,リミテッド ライアビリティ カンパニー | Platelet-derived growth factor compositions and methods for treating tendon disorders |
JO3340B1 (en) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | Antibodies to human gdf8 |
AR081556A1 (en) | 2010-06-03 | 2012-10-03 | Glaxo Group Ltd | HUMANIZED ANTIGEN UNION PROTEINS |
AU2011292197B2 (en) | 2010-08-16 | 2015-05-28 | Amgen Inc. | Antibodies that bind myostatin, compositions and methods |
PE20140135A1 (en) | 2010-08-20 | 2014-02-20 | Wyeth Llc | OSTEOGENIC DESIGN PROTEIN |
US9688735B2 (en) | 2010-08-20 | 2017-06-27 | Wyeth Llc | Designer osteogenic proteins |
AU2011337704B2 (en) | 2010-11-30 | 2017-06-15 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
ES2663946T3 (en) | 2011-11-14 | 2018-04-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods to increase muscle mass and strength by specifically antagonizing GDF8 and / or Activin A |
SG11201403367YA (en) | 2011-12-19 | 2014-07-30 | Amgen Inc | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
JP6433889B2 (en) | 2012-06-15 | 2018-12-05 | ファイザー・インク | Improved antagonistic antibodies against GDF-8 and uses thereof |
US10034945B2 (en) | 2012-07-13 | 2018-07-31 | Trustees Of Tufts College | Silk powder compaction for production of constructs with high mechanical strength and stiffness |
ES2791778T3 (en) | 2012-08-01 | 2020-11-05 | Ikaika Therapeutics Llc | Mitigation of tissue damage and fibrosis through anti-LTBP4 antibodies |
EP3597747B1 (en) | 2012-08-24 | 2023-03-15 | Chugai Seiyaku Kabushiki Kaisha | Mouse fcgammarii-specific fc antibody |
SG10201709559PA (en) | 2012-08-24 | 2017-12-28 | Chugai Pharmaceutical Co Ltd | Fcγriib-specific fc region variant |
MY172863A (en) | 2012-09-13 | 2019-12-13 | Bristol Myers Squibb Co | Fibronectin based scaffold domain proteins that bind to myostatin |
MX2015009901A (en) | 2013-02-01 | 2016-04-06 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject. |
US11267868B2 (en) | 2013-04-02 | 2022-03-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
SG10201913751RA (en) | 2013-05-06 | 2020-03-30 | Scholar Rock Inc | Compositions and methods for growth factor modulation |
TW201920262A (en) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | Anti-activin A antibodies and uses thereof |
CA3005158A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
WO2016073879A2 (en) * | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related antibodies and uses thereof |
PE20221834A1 (en) | 2014-12-19 | 2022-11-29 | Chugai Pharmaceutical Co Ltd | ANTIMYOSTATIN ANTIBODIES |
KR20170110129A (en) | 2015-02-05 | 2017-10-10 | 추가이 세이야쿠 가부시키가이샤 | Antibodies comprising ionic concentration dependent antigen binding domains, Fc region variants, antibodies that bind to IL-8, and their use |
MA41795A (en) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN |
EP3283519A1 (en) | 2015-04-15 | 2018-02-21 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
LT3350220T (en) | 2015-09-15 | 2021-09-27 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
JP2018530560A (en) | 2015-10-09 | 2018-10-18 | サレプタ セラピューティクス, インコーポレイテッド | Compositions and methods for the treatment of Duchenne muscular dystrophy and related disorders |
JP7025021B2 (en) | 2015-10-26 | 2022-02-24 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Reduced and oxidized polysaccharides and methods of their use |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
CN109071645A (en) | 2016-01-08 | 2018-12-21 | 供石公司 | Anti- Promyostatin/latent flesh amicine antibody and its application method |
KR102271635B1 (en) | 2016-06-13 | 2021-07-06 | 스칼러 락, 인크. | Uses and Combination Therapies of Myostatin Inhibitors |
KR102456739B1 (en) | 2016-06-17 | 2022-10-19 | 추가이 세이야쿠 가부시키가이샤 | Anti-myostatin antibodies and methods of use |
CN116251182A (en) | 2016-08-05 | 2023-06-13 | 中外制药株式会社 | Compositions for preventing or treating IL-8 related diseases |
FI3565592T3 (en) | 2017-01-06 | 2023-05-10 | Scholar Rock Inc | Treating metabolic diseases by inhibiting myostatin activation |
CN111787981A (en) | 2018-03-01 | 2020-10-16 | 瑞泽恩制药公司 | Method of altering body composition |
CN113195532A (en) | 2018-12-18 | 2021-07-30 | 瑞泽恩制药公司 | Compositions and methods for increasing body weight and lean muscle mass using antagonists against leptin receptor, GDF8, and activin A |
CN113347990A (en) | 2018-12-21 | 2021-09-03 | 西北大学 | Use of annexin in prevention and treatment of muscularis damage |
WO2020139977A1 (en) | 2018-12-26 | 2020-07-02 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
JP7375525B2 (en) * | 2019-12-23 | 2023-11-08 | 株式会社島津製作所 | Patient authentication system and patient authentication method |
JP7397822B2 (en) | 2021-05-14 | 2023-12-13 | 花王株式会社 | Oral patch sheet |
WO2024064842A1 (en) | 2022-09-21 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4766073A (en) * | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
ES2083469T3 (en) | 1989-11-22 | 1996-04-16 | Genentech Inc | PEPTIDO ASSOCIATED WITH A LATENCY AND USES OF THE SAME. |
AU7312891A (en) * | 1990-02-12 | 1991-09-03 | Board Of Regents, The University Of Texas System | Satellite cell proliferation in adult skeletal muscle |
JP3415643B2 (en) * | 1992-12-04 | 2003-06-09 | 株式会社ミノファーゲン製薬 | Drugs for muscular dystrophy |
DE69432815T2 (en) | 1993-03-19 | 2003-12-11 | Univ Johns Hopkins Med | GROWTH FACTOR-8 |
US5994618A (en) * | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
DK0776337T3 (en) | 1994-07-08 | 2005-12-12 | Univ Johns Hopkins Med | Growth differentiation factor-11 |
US5616561A (en) | 1995-03-31 | 1997-04-01 | Regents Of The University Of California | TGF-β antagonists as mitigators of radiation-induced tissue damage |
AU6274298A (en) | 1997-02-05 | 1998-08-25 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-8 |
DE69841139D1 (en) | 1997-07-14 | 2009-10-22 | Univ Liege | MUTATIONS IN MYOSTATINGEN INCREASE MUSCLE MASS IN MAMMALS |
US6656475B1 (en) * | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
CA2319703C (en) | 1998-02-05 | 2005-09-20 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
-
1994
- 1994-03-18 DE DE69432815T patent/DE69432815T2/en not_active Expired - Lifetime
- 1994-03-18 DK DK94912274T patent/DK0690873T3/en active
- 1994-03-18 EP EP03006413A patent/EP1333035A3/en not_active Ceased
- 1994-03-18 ES ES94912274T patent/ES2201076T3/en not_active Expired - Lifetime
- 1994-03-18 WO PCT/US1994/003019 patent/WO1994021681A1/en active IP Right Grant
- 1994-03-18 JP JP6521293A patent/JPH09507829A/en active Pending
- 1994-03-18 US US08/525,596 patent/US5827733A/en not_active Expired - Lifetime
- 1994-03-18 EP EP94912274A patent/EP0690873B1/en not_active Expired - Lifetime
- 1994-03-18 CA CA002157577A patent/CA2157577C/en not_active Expired - Lifetime
-
1998
- 1998-10-23 US US09/177,860 patent/US6096506A/en not_active Expired - Lifetime
-
2000
- 2000-08-01 US US09/629,938 patent/US6500664B1/en not_active Expired - Lifetime
-
2002
- 2002-12-31 US US10/335,483 patent/US7179884B2/en not_active Expired - Fee Related
-
2004
- 2004-01-06 JP JP2004001012A patent/JP2004121265A/en active Pending
-
2005
- 2005-11-10 JP JP2005326630A patent/JP2006117682A/en active Pending
-
2007
- 2007-01-29 US US11/700,267 patent/US7534432B2/en not_active Expired - Fee Related
- 2007-05-09 JP JP2007125060A patent/JP2007306920A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US7179884B2 (en) | 2007-02-20 |
JP2006117682A (en) | 2006-05-11 |
US7534432B2 (en) | 2009-05-19 |
EP1333035A3 (en) | 2004-07-07 |
JPH09507829A (en) | 1997-08-12 |
ES2201076T3 (en) | 2004-03-16 |
US5827733A (en) | 1998-10-27 |
CA2157577C (en) | 2009-11-17 |
WO1994021681A1 (en) | 1994-09-29 |
EP0690873A4 (en) | 2000-11-22 |
DK0690873T3 (en) | 2003-09-29 |
JP2004121265A (en) | 2004-04-22 |
US6096506A (en) | 2000-08-01 |
EP0690873B1 (en) | 2003-06-11 |
EP1333035A2 (en) | 2003-08-06 |
DE69432815T2 (en) | 2003-12-11 |
JP2007306920A (en) | 2007-11-29 |
US6500664B1 (en) | 2002-12-31 |
US20030120058A1 (en) | 2003-06-26 |
US20070185321A1 (en) | 2007-08-09 |
DE69432815D1 (en) | 2003-07-17 |
EP0690873A1 (en) | 1996-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2157577A1 (en) | Growth differentiation factor-8 | |
CA2153653A1 (en) | Growth differentiation factor-9 | |
Corey et al. | Generation of a hybrid sequence-specific single-stranded deoxyribonuclease | |
Miska et al. | HDAC4 deacetylase associates with and represses the MEF2 transcription factor | |
US6514706B1 (en) | Linear amplification mediated PCR (LAM PCR) | |
Gross et al. | RNA 5′-triphosphatase, nucleoside triphosphatase, and guanylyltransferase activities of baculovirus LEF-4 protein | |
KR860001515B1 (en) | Process of replication and translation of human pre-growth hormone | |
CA2165297A1 (en) | Myeloid cell leukemia associated gene mcl-1 | |
Krippl et al. | Functions of purified E1A protein microinjected into mammalian cells. | |
Wakita et al. | Higher-order structure of bovine mitochondrial tRNA Phe lacking the ‘conserved’GG and TΨCG sequences as inferred by enzymatic and chemical probing | |
CA2222279A1 (en) | Hypoxia inducible factor-1 and method of use | |
Vanderslice et al. | Cloning and nucleotide sequence of wild type and a mutant histidine decarboxylase from Lactobacillus 30a. | |
Mikhailov et al. | Baculovirus alkaline nuclease possesses a 5′→ 3′ exonuclease activity and associates with the DNA-binding protein LEF-3 | |
US20060147937A1 (en) | Isolation of living cells and preparation of cell lines based on detection and quantification of preselected cellular ribonucleic acid sequences | |
Young et al. | Bacteriophage T4 gene transcription studied by hybridization to cloned restriction fragments | |
Tissières et al. | Breakdown of messenger RNA during in vitro amino acid incorporation into proteins | |
Dunn et al. | The transcription termination site at the end of the early region of bacteriophage T7 DNA | |
Christopoulos et al. | Expression immunoassay. Antigen quantitation using antibodies labeled with enzyme-coding DNA fragments | |
Field et al. | Cloning, sequencing, and demonstration of polymorphism in trypanothione reductase from Crithidia fasciculata | |
Wysor et al. | On the mode of action of silver sulfadiazine | |
Locker et al. | [1] An overview of mitochondrial nucleic acids and biogenesis | |
Semsey et al. | Identification of site-specific recombination genes int and xis of the Rhizobium temperate phage 16-3 | |
Turchi et al. | DNA helicase E and DNA polymerase. epsilon. functionally interact for displacement synthesis | |
CA2374377A1 (en) | Potassium channel kcnq5 | |
saiga et al. | Properties of in vitro trarscription by isolated Xenopus oocyte nucleoli |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20140318 |